Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial

about

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial

Item

http://www.wikidata.org/entity/Q58764607

description

scientific article published on 04 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Pirfenidone in patients with u ...... cebo-controlled phase II trial

@en

Pirfenidone in patients with u ...... cebo-controlled phase II trial

@nl

type

Item

label

Pirfenidone in patients with u ...... cebo-controlled phase II trial

@en

Pirfenidone in patients with u ...... cebo-controlled phase II trial

@nl

prefLabel

Pirfenidone in patients with u ...... cebo-controlled phase II trial

@en

Pirfenidone in patients with u ...... cebo-controlled phase II trial

@nl

P1476

Pirfenidone in patients with u ...... cebo-controlled phase II trial

@en

P2093

Aryeh Fischer

http://www.w3.org/2001/XMLSchema#string

David J Lederer

http://www.w3.org/2001/XMLSchema#string

Judit Axmann

http://www.w3.org/2001/XMLSchema#string

Klaus-Uwe Kirchgaessler

http://www.w3.org/2001/XMLSchema#string

Maria Molina-Molina

http://www.w3.org/2001/XMLSchema#string

Michael Kreuter

http://www.w3.org/2001/XMLSchema#string

Tamera J Corte

http://www.w3.org/2001/XMLSchema#string

Vincent Cottin

http://www.w3.org/2001/XMLSchema#string

P2860

Unclassifiable interstitial lung disease: A review

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Soci

A cohort study of interstitial lung diseases in central Denmark

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias

MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis

Unclassifiable interstitial lung diseases: Clinical characteristics and survival

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

P304

e000289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJRESP-2018-000289

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Toby Maher

P577

2018-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30233802

http://www.w3.org/2001/XMLSchema#string

P921

placebo

P932

6135451

http://www.w3.org/2001/XMLSchema#string